Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirsten M Timms

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
The American Journal of Gastroenterology|September 27, 2007
IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel diseaseRebecca L Roberts, Richard B Gearry, Jade E Hollis-Moffatt, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 10, 2024
Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay PerformanceMarcel Romey, Fiona Rodepeter, Akira Hattesohl, et al.
Obstetrics & Gynecology Science|September 3, 2020
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancerRoshni D Kalachand, Ciaran O'Riain, Sinead Toomey, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 19, 2021
Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancerTamara L Lotan, Harsimar B Kaur, Daniela C Salles, et al.
Breast Cancer Research : BCR|December 6, 2014
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypesKirsten M Timms, Victor Abkevich, Elisha Hughes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
Genomic and Clinicopathologic Characterization of <i>ATM</i>-deficient Prostate CancerHarsimar Kaur, Daniela C Salles, Sanjana Murali, et al.
Molecular Cancer Research : MCR|May 5, 2018
Biomarker Assessment of HR Deficiency, Tumor <i>BRCA1/2</i> Mutations, and <i>CCNE1</i> Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum MonotherapyEuan A Stronach, James Paul, Kirsten M Timms, et al.
Gynecologic Oncology|November 7, 2021
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trialDarren R Hodgson, Jessica S Brown, Simon P Dearden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2011
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancerAna M Gonzalez-Angulo, Kirsten M Timms, Shuying Liu, et al.
Breast Cancer Research and Treatment|December 25, 2017
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancerMelinda L Telli, Jessica Hellyer, William Audeh, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
The American Journal of Gastroenterology|September 27, 2007
IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel diseaseRebecca L Roberts, Richard B Gearry, Jade E Hollis-Moffatt, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 10, 2024
Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay PerformanceMarcel Romey, Fiona Rodepeter, Akira Hattesohl, et al.
Obstetrics & Gynecology Science|September 3, 2020
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancerRoshni D Kalachand, Ciaran O'Riain, Sinead Toomey, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 19, 2021
Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancerTamara L Lotan, Harsimar B Kaur, Daniela C Salles, et al.
Breast Cancer Research : BCR|December 6, 2014
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypesKirsten M Timms, Victor Abkevich, Elisha Hughes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
Genomic and Clinicopathologic Characterization of <i>ATM</i>-deficient Prostate CancerHarsimar Kaur, Daniela C Salles, Sanjana Murali, et al.
Molecular Cancer Research : MCR|May 5, 2018
Biomarker Assessment of HR Deficiency, Tumor <i>BRCA1/2</i> Mutations, and <i>CCNE1</i> Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum MonotherapyEuan A Stronach, James Paul, Kirsten M Timms, et al.
Gynecologic Oncology|November 7, 2021
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trialDarren R Hodgson, Jessica S Brown, Simon P Dearden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2011
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancerAna M Gonzalez-Angulo, Kirsten M Timms, Shuying Liu, et al.
Breast Cancer Research and Treatment|December 25, 2017
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancerMelinda L Telli, Jessica Hellyer, William Audeh, et al.
Pageof 4